Clinical trial
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus…
NCT00480363 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00480363 |
|---|---|
| Title | QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression |
| Official title | QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression |
| Acronym | QUIREDEX |
| Lead sponsor | PETHEMA Foundation, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Procedure |
| Interventions | Maintenance with lower doses of lenalidomide and dexamethasone |
| Enrollment | 120 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Jul 1, 2013 |
| First posted | May 30, 2007 |
| Last update posted | Jul 31, 2013 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: